This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mario Cristofolini, MD; Sebastiana Boi, MD; Salvatore Girlando, DSc; Giuseppe Zumiani, MD; Paolo Cristofolini, MD; Paolo Dalla Palma, MD
Trento, Italy

Claudio Doglioni, MD
Feltre, Italy

Mattia Barbareschi, MD
Department of Pathology S Chiara Hospital 38100 Trento, Italy

Arch Dermatol. 1994;130(4):518-519.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We appreciated very much the comments by McGregor et al concerning our article dealing with p53 expression in human nevi and melanomas.¹ We completely agree with McGregor et al concerning the prognostic significance of p53 immunoreactivity. We, too, are interested in evaluating p53 immunoreactivity in human neoplasms in relation to its possible value as a predictor of more aggressive disease.^2,3 However, our comments¹ were not aimed at denying the possible prognostic value of p53 immunoreactivity in skin melanomas. Indeed, we found a higher percentage of p53-positive cases among melanoma metastases than in primary lesions, a fact that may be supportive of the hypothesis that p53 accumulation in melanomas might be correlated with tumor progression. Moreover, as shown in the table on page 740 of our article,¹ the prevalence of thin melanomas in the group with more than 1% of positive cells is low (one of seven . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?